纳武利尤单抗联合伊匹木单抗对比舒尼替尼一线治疗晚期肾细胞癌:III期CheckMate 214试验最终疗效与安全性分析
CheckMate 214研究最终分析显示,中位随访9.3年,纳武利尤单抗联合伊匹木单抗对比舒尼替尼在晚期肾细胞癌意向治疗人群(HR 0.71)和中/低风险人群(HR 0.69)中维持显著总生存获益,且缓解持久,3-4级治疗相关不良事件发生率更低。联合方案仍是晚期肾细胞癌一线标准治疗。
要点
- 中位随访9.3年,NIVO+IPI在ITF人群HR 0.71,中/低风险HR 0.69,持续生存获益。
- 108个月OS率:NIVO+IPI组31.4% vs SUN组19.5%(ITT人群)。
- 3-4级治疗相关AE:NIVO+IPI组48.6% vs SUN组64.1%。
核心结论
- 在中位随访9.3年的III期CheckMate 214最终分析中,NIVO+IPI对比SUN在晚期肾细胞癌一线治疗中维持显著总生存获益和持久缓解。
- NIVO+IPI组3-4级治疗相关不良事件发生率低于SUN组。
- NIVO+IPI仍是晚期肾细胞癌一线标准治疗。
研究设计与样本
- III期CheckMate 214试验(NCT02231749),随机对照,共入组1096例既往未治疗的晚期肾细胞癌患者。
- 患者随机接受NIVO 3 mg/kg联合IPI 1 mg/kg每3周×4次后NIVO维持,或SUN 50 mg每日一次(服4周停2周)。
- 主要终点为IMDC中/低风险人群的OS、独立影像评审委员会评估的PFS和ORR;次要终点为ITT人群;探索性终点为IMDC favourable风险人群。
主要发现
- 中位随访9.3年(范围8.6-9.9年),NIVO+IPI对比SUN的OS HR(95%CI)在ITT人群为0.71(0.62-0.82),中/低风险人群为0.69(0.59-0.81),favourable风险人群为0.80(0.59-1.09)。
- 108个月OS概率NIVO+IPI vs SUN分别为:ITT 31.4% vs 19.5%,中/低风险 30.2% vs 18.7%,favourable风险 35.3% vs 21.8%。
- 96个月PFS概率NIVO+IPI vs SUN分别为:ITT 22.7% vs 9.0%,中/低风险 25.4% vs 8.5%,favourable风险 12.5% vs 11.3%。
- 96个月维持缓解概率NIVO+IPI vs SUN分别为:ITT 48.0% vs 19.0%,中/低风险 50.0% vs 23.0%,favourable风险 36.0% vs 不可估计。
- 任何级别(3-4级)治疗相关不良事件发生率:NIVO+IPI组94.1%(48.6%),SUN组97.6%(64.1%)。
临床怎么用
- 对于既往未治疗的晚期肾细胞癌患者,尤其是IMDC中/低风险人群,NIVO+IPI一线治疗可带来长期生存获益和持久缓解。
- NIVO+IPI的3-4级治疗相关不良事件发生率低于SUN,安全性可控。
- NIVO+IPI应继续作为晚期肾细胞癌一线标准治疗选择。
局限性
- favourable风险人群为探索性分析,OS HR 0.80(95%CI 0.59-1.09)未显示显著获益。
- 免疫介导不良事件停药与OS关系的分析为探索性事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nivolumab plus ipilimumab (NIVO + IPI) demonstrated significant long-term survival and response benefits in patients with previously untreated advanced renal cell carcinoma (aRCC) in the phase III CheckMate 214 trial (NCT02231749). We report final efficacy and safety results with 9.3 years median follow-up. PATIENTS AND METHODS: Patients (N = 1096) were randomized to NIVO 3 mg/kg plus IPI 1 mg/kg every 3 weeks × four doses, followed by NIVO (3 mg/kg or 240 mg every 2 weeks or 480 mg every 4 weeks); or sunitinib (SUN) (50 mg) once daily (4 weeks on, 2 weeks off). ENDPOINTS: overall survival (OS), and independent radiology review committee-assessed progression-free survival and objective response rate in International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) intermediate/poor-risk (primary), intention-to-treat (secondary), and IMDC favorable-risk (exploratory) patients. RESULTS: With a median (range) follow-up of 9.3 years (8.6-9.9 years), the hazard ratio (95% confidence interval) for OS with NIVO + IPI versus SUN was 0.71 (0.62-0.82) in intention-to-treat patients, 0.69 (0.59-0.81) in intermediate/poor-risk patients, and 0.80 (0.59-1.09) in favorable-risk patients; 108-month OS probabilities were 31.4% versus 19.5%, 30.2% versus 18.7%, and 35.3% versus 21.8%, respectively. Progression-free survival probabilities at 96 months were 22.7% versus 9.0% (intention-to-treat), 25.4% versus 8.5% (intermediate/poor risk), and 12.5% versus 11.3% (favorable risk). Probabilities of remaining in response at 96 months with NIVO + IPI versus SUN were 48.0% versus 19.0% (intention-to-treat), 50.0% versus 23.0% (intermediate/poor risk), and 36.0% versus not estimable (favorable risk). Incidence of any-grade (grade 3-4) treatment-related adverse events (AEs) was 94.1% (48.6%) with NIVO + IPI versus 97.6% (64.1%) with SUN. Exploratory post hoc analyses reported include descriptive analyses of OS by immune-mediated AE discontinuation status. CONCLUSIONS: In the longest phase III follow-up of a first-line checkpoint inhibitor combination in aRCC (>9 years), NIVO + IPI maintained a substantial survival benefit with durable responses versus SUN. Grade 3-4 treatment-related AEs were lower with NIVO + IPI versus SUN at 9 years. NIVO + IPI remains a first-line standard of care in aRCC.
引用
- Choueiri TK, Albigès L, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol. 2026. PMID: 41786248. doi:10.1016/j.annonc.2026.02.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。